Autosomal Recessive Hereditary Spastic Paraplegia: A Rare Case of a Family with Phenotypic Variation

Q4 Pharmacology, Toxicology and Pharmaceutics
M. Saban, Tal Shachar
{"title":"Autosomal Recessive Hereditary Spastic Paraplegia: A Rare Case of a Family with Phenotypic Variation","authors":"M. Saban, Tal Shachar","doi":"10.2174/1875692117999201211142908","DOIUrl":null,"url":null,"abstract":"\n\n Hereditary spastic paraplegia is a neurodegenerative disorder\nwith a pure and complex form. More than 50 genetic types are currently known, with different\nages of onset for characteristic symptoms. Data regarding hereditary spastic paraplegia\nremain scarce, and the rare subtype of spastic paraplegia type 5 is no exception.\n\n\n\n This report presents data regarding the case of a single family, from the city of\nDjerba, with five individuals affected with hereditary spastic paraplegia, the largest number\nof spastic paraplegia type 5 mutated family members so far reported in current literature.\n\n\n\nTo emphasize the importance of genetic testing, we retrospectively reviewed a\nfamilial confirmed case of hereditary spastic paraplegia. Clinical features of family members\nwere described.\n\n\n\nThe family presents a large phenotypic variation that, in part, differs from the\nknown phenotypic presentations. Age of onset and clinical manifestation showed interfamilial\nvariations. The alteration found in CYP7B1 (c.1081C>T; p.R361*) may help emphasize\nthe importance of genetic testing and the much-needed treatment options already\nin use in current neurological practice.\n\n\n\n The understanding of the molecular pathways of hereditary spastic paraplegia,\ntogether with the establishment of disease biomarkers, will hopefully lead to better\nand more personalized treatment.\n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"62 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692117999201211142908","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Hereditary spastic paraplegia is a neurodegenerative disorder with a pure and complex form. More than 50 genetic types are currently known, with different ages of onset for characteristic symptoms. Data regarding hereditary spastic paraplegia remain scarce, and the rare subtype of spastic paraplegia type 5 is no exception. This report presents data regarding the case of a single family, from the city of Djerba, with five individuals affected with hereditary spastic paraplegia, the largest number of spastic paraplegia type 5 mutated family members so far reported in current literature. To emphasize the importance of genetic testing, we retrospectively reviewed a familial confirmed case of hereditary spastic paraplegia. Clinical features of family members were described. The family presents a large phenotypic variation that, in part, differs from the known phenotypic presentations. Age of onset and clinical manifestation showed interfamilial variations. The alteration found in CYP7B1 (c.1081C>T; p.R361*) may help emphasize the importance of genetic testing and the much-needed treatment options already in use in current neurological practice. The understanding of the molecular pathways of hereditary spastic paraplegia, together with the establishment of disease biomarkers, will hopefully lead to better and more personalized treatment.
常染色体隐性遗传性痉挛性截瘫:一例罕见的家族表型变异
遗传性痉挛性截瘫是一种单纯而复杂的神经退行性疾病。目前已知的基因类型超过50种,具有不同的特征症状。关于遗传性痉挛性截瘫的资料仍然很少,罕见的痉挛性截瘫5型也不例外。本报告提供了来自杰尔巴市的一个家庭的病例数据,该家庭有5个人患有遗传性痉挛性截瘫,这是目前文献中报道的痉挛性截瘫5型突变家庭成员数量最多的病例。为了强调基因检测的重要性,我们回顾了一例家族性的遗传性痉挛性截瘫病例。描述了家庭成员的临床特征。该家族表现出很大的表型变异,部分不同于已知的表型表现。发病年龄和临床表现存在家族间差异。CYP7B1发生改变(c.1081C>T;p.R361*)可能有助于强调基因检测的重要性以及目前神经学实践中已经使用的急需的治疗方案。对遗传性痉挛性截瘫分子途径的了解,以及疾病生物标志物的建立,将有望带来更好、更个性化的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Pharmacogenomics and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
0.40
自引率
0.00%
发文量
11
期刊介绍: Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信